BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 30455242)

  • 1. Omadacycline Gut Microbiome Exposure Does Not Induce Clostridium difficile Proliferation or Toxin Production in a Model That Simulates the Proximal, Medial, and Distal Human Colon.
    Moura IB; Buckley AM; Ewin D; Shearman S; Clark E; Wilcox MH; Chilton CH
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection.
    Chilton CH; Crowther GS; Todhunter SL; Nicholson S; Freeman J; Chesnel L; Wilcox MH
    J Antimicrob Chemother; 2014 Sep; 69(9):2426-33. PubMed ID: 24816211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of the effect of the adsorbent DAV131A on the propensity of moxifloxacin to induce simulated Clostridioides (Clostridium) difficile infection (CDI) in an in vitro human gut model.
    Chilton CH; Crowther GS; Miossec C; de Gunzburg J; Andremont A; Wilcox MH
    J Antimicrob Chemother; 2020 Jun; 75(6):1458-1465. PubMed ID: 32097465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential of lactoferrin to prevent antibiotic-induced Clostridium difficile infection.
    Chilton CH; Crowther GS; Śpiewak K; Brindell M; Singh G; Wilcox MH; Monaghan TM
    J Antimicrob Chemother; 2016 Apr; 71(4):975-85. PubMed ID: 26759363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection.
    Chilton CH; Crowther GS; Baines SD; Todhunter SL; Freeman J; Locher HH; Athanasiou A; Wilcox MH
    J Antimicrob Chemother; 2014 Mar; 69(3):697-705. PubMed ID: 24128668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model.
    Baines SD; Saxton K; Freeman J; Wilcox MH
    J Antimicrob Chemother; 2006 Nov; 58(5):1062-5. PubMed ID: 17030519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model.
    Chilton CH; Freeman J; Crowther GS; Todhunter SL; Wilcox MH
    J Antimicrob Chemother; 2012 Oct; 67(10):2434-7. PubMed ID: 22723601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure.
    Chilton CH; Crowther GS; Freeman J; Todhunter SL; Nicholson S; Longshaw CM; Wilcox MH
    J Antimicrob Chemother; 2014 Feb; 69(2):451-62. PubMed ID: 24003182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of antimicrobial activity of ceftaroline against Clostridium difficile and propensity to induce C. difficile infection in an in vitro human gut model.
    Baines SD; Chilton CH; Crowther GS; Todhunter SL; Freeman J; Wilcox MH
    J Antimicrob Chemother; 2013 Aug; 68(8):1842-9. PubMed ID: 23557928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection.
    Crowther GS; Baines SD; Todhunter SL; Freeman J; Chilton CH; Wilcox MH
    J Antimicrob Chemother; 2013 Jan; 68(1):168-76. PubMed ID: 22966180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of vancomycin extended-dosing regimens for treatment of simulated Clostridium difficile infection within an in vitro human gut model.
    Crowther GS; Chilton CH; Longshaw C; Todhunter SL; Ewin D; Vernon J; Karas A; Wilcox MH
    J Antimicrob Chemother; 2016 Apr; 71(4):986-91. PubMed ID: 26755495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model.
    Baines SD; Noel AR; Huscroft GS; Todhunter SL; O'Connor R; Hobbs JK; Freeman J; Lovering AM; Wilcox MH
    J Antimicrob Chemother; 2011 Jul; 66(7):1537-46. PubMed ID: 21504940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model.
    Chilton CH; Crowther GS; Todhunter SL; Ashwin H; Longshaw CM; Karas A; Wilcox MH
    J Antimicrob Chemother; 2015 Sep; 70(9):2598-607. PubMed ID: 26078392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model.
    Freeman J; Marquis M; Crowther GS; Todhunter SL; Fawley WN; Chilton CH; Moeck G; Lehoux D; Wilcox MH
    J Antimicrob Chemother; 2012 Dec; 67(12):2919-26. PubMed ID: 22899803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut.
    Freeman J; O'Neill FJ; Wilcox MH
    J Antimicrob Chemother; 2003 Jul; 52(1):96-102. PubMed ID: 12775682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence of dual-strain Clostridium difficile infection in an in vitro human gut model.
    Crowther GS; Chilton CH; Todhunter SL; Nicholson S; Freeman J; Wilcox MH
    J Antimicrob Chemother; 2015 Aug; 70(8):2316-21. PubMed ID: 25925596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences of the Fecal Microflora With Clostridium difficile Therapies.
    Louie TJ; Byrne B; Emery J; Ward L; Krulicki W; Nguyen D; Wu K; Cannon K
    Clin Infect Dis; 2015 May; 60 Suppl 2():S91-7. PubMed ID: 25922407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mixed infection by Clostridium difficile in an in vitro model of the human gut.
    Baines SD; Crowther GS; Todhunter SL; Freeman J; Chilton CH; Fawley WN; Wilcox MH
    J Antimicrob Chemother; 2013 May; 68(5):1139-43. PubMed ID: 23354280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model.
    Baines SD; O'Connor R; Saxton K; Freeman J; Wilcox MH
    J Antimicrob Chemother; 2009 Mar; 63(3):520-5. PubMed ID: 19112083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model.
    Baines SD; Freeman J; Wilcox MH
    J Antimicrob Chemother; 2005 Jun; 55(6):974-82. PubMed ID: 15860551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.